Parkinson’s disease (PD) is a chronically progressive neurodegenerative disorder, for which disease-modifying therapies are currently not available. The neuropathological hallmark of PD is a progressive degeneration of dopaminergic neurons in the substantia nigra accompanied by intracellular aggregates, which are predominantly composed of the protein alpha-synuclein. In this work, the neuroprotective efficacy of specific phosphodiesterase-inhibitors was evaluated in a human cellular alpha-synuclein-toxicity-model. The PDE1-inhibitor Vinpocetine was identified and validated as a neuroprotective.
«
Parkinson’s disease (PD) is a chronically progressive neurodegenerative disorder, for which disease-modifying therapies are currently not available. The neuropathological hallmark of PD is a progressive degeneration of dopaminergic neurons in the substantia nigra accompanied by intracellular aggregates, which are predominantly composed of the protein alpha-synuclein. In this work, the neuroprotective efficacy of specific phosphodiesterase-inhibitors was evaluated in a human cellular alpha-synucl...
»